2162 Stock Overview
A biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Keymed Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$38.20 |
| 52 Week High | HK$57.30 |
| 52 Week Low | HK$26.60 |
| Beta | -0.067 |
| 11 Month Change | -12.98% |
| 3 Month Change | 17.90% |
| 1 Year Change | -29.06% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -37.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2162 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -2.9% | -0.3% | -0.6% |
| 1Y | -29.1% | -15.2% | 9.6% |
Return vs Industry: 2162 underperformed the Hong Kong Biotechs industry which returned -15.2% over the past year.
Return vs Market: 2162 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 2162 volatility | |
|---|---|
| 2162 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2162 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2162's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 1,116 | Bo Chen | www.keymedbio.com |
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD.
Keymed Biosciences Inc. Fundamentals Summary
| 2162 fundamental statistics | |
|---|---|
| Market cap | HK$10.53b |
| Earnings (TTM) | -HK$798.33m |
| Revenue (TTM) | HK$87.72m |
120.0x
P/S Ratio-13.2x
P/E RatioIs 2162 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2162 income statement (TTM) | |
|---|---|
| Revenue | CN¥81.65m |
| Cost of Revenue | CN¥25.60m |
| Gross Profit | CN¥56.06m |
| Other Expenses | CN¥799.13m |
| Earnings | -CN¥743.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.70 |
| Gross Margin | 68.65% |
| Net Profit Margin | -910.03% |
| Debt/Equity Ratio | 27.3% |
How did 2162 perform over the long term?
See historical performance and comparison